Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GLUE
SELLMonte Rosa Therapeutics, Inc. · Healthcare · United States · $1.9B · Avg Vol: $34M/d
COMPANY DESCRIPTION
Monte Rosa Therapeutics is an early-stage biotechnology company developing novel precision medicines that leverage its proprietary molecular glue degrader platform to target and eliminate disease-causing proteins. Its competitive edge lies in this innovative platform, which enables the degradation of historically undruggable targets, opening new therapeutic avenues. The company focuses on developing treatments for difficult-to-treat cancers and other intractable diseases.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 75.6M | 123.7M | 63.5% | 43.0M | 44.5M | 58.2M | -31.4% |
| EPS | -2.96 | -2.30 | -2.63 | -1.18 | -0.59 | — | -1.42 | -1.59 | -1.81 | — |
| Shares | — | 49.3M | 50.1M | 61.5M | 65.5M | +32.9% | 84.5M | — | — | — |
| Debt | — | 47.0M | 46.0M | 42.7M | 39.2M | -5.9% | 39.1M | — | — | — |
| Equity | — | 271.4M | 179.3M | 222.9M | 233.1M | -5.0% | — | — | — | — |
| Op CF | — | -92.5M | -43.8M | 42.0M | -22.8M | — | -14.7M | — | — | — |
| Inv CF | — | -219.2M | 88.8M | -44.5M | -101.8M | — | — | — | — | — |
| Fin CF | — | 20.5M | 27.5M | 98.9M | 30.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GLUE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc.(you) | $1.9B | 24 | SELL |
| STOK | Stoke Therapeutics, Inc. | $1.8B | 27 | SELL |
| TYRA | Tyra Biosciences, Inc. | $1.8B | 21 | SELL |
| SION | Sionna Therapeutics, Inc. | $2.1B | 28 | SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 30 | SELL |
| NUVB | Nuvation Bio Inc. | $2.2B | 28 | SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 18 | STRONG SELL |
| BHVN | Biohaven Ltd. | $2.2B | 20 | STRONG SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%